Protecção de séniores em lares

Surveillance of COVID-19 at long-term care facilities in the EU/EEA: It is of paramount importance to be able to rapidly identify, assess and control COVID-19 outbreaks in LTCFs in order to protect this particularly fragile population

Apps para a vigilância

Tracing Apps to Fight Covid-19: Are surveillance technologies effective?

Vaccine experts say Moderna's Covid-19 data leave big questions

Vaccine experts say Moderna's Covid-19 data leave big questions: Heavy hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects. The company’s stock valuation also surged, hitting $29 billion, an astonishing feat for a company that currently sells zero products.

But was there good reason for so much enthusiasm? Several vaccine experts asked by STAT concluded that, based on the information made available by the Cambridge, Mass.-based company, there’s really no way to know how impressive — or not — the vaccine may be.

While Moderna blitzed the media, it revealed very little information — and most of what it did disclose were words, not data. That’s important: If you ask scientists to read a journal article, they will scour data tables, not corporate statements. With science, numbers speak much louder than words.

WHO: Key criteria for the ethical acceptability of COVID-19 human challenge studies

"Policy Brief" das Nações Unidas

COVID-19 and the Need for Action on Mental Health: Policy Brief

CovidCheck.pt é um projeto de divulgação informativa do MediaLab_Iscte, em colaboração com a SPP e o Cenjor

Corruption and COVID-19: produced by the Center for International Private Enterprise (CIPE)